Alto Neuroscience Inc (ANRO) News

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights

– Favorable outcome from interim analysis of ongoing ALTO-300 Phase 2b MDD trial; topline results expected in mid-2026 – – Completed enrollment...

Christopher Nixon Cox Named Chairman of High-Trend International Group

Christopher Nixon Cox Named Chairman of High-Trend International Group PR Newswire SINGAPORE, March 13, 2025 SINGAPORE, March 13, 2025...

Alto Neuroscience to Participate in Upcoming Investor Conferences

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines...

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

– Patent supports Alto’s precision approach to improve patient selection – Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage...

Form 8-K - Current report

Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial

– Interim analysis resulted in a recommendation to continue the study with a total targeted biomarker population of ~200 patients in the final...

Form EFFECT - Notice of Effectiveness

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form S-3 - Registration statement under Securities Act of 1933